CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis

Journal of Immunology

Volumn 176, Issue 3, 2006, Pages 1456-1464

  Pan, Judong ^a   Burdick, Marie D ^a   Belperio, John A ^a   Xue, Ying Ying ^a   Gerard, Craig ^b   Sharma, Sherven ^a   Dubinett, Steven M ^a   Strieter, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; INTERLEUKIN 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELLULAR IMMUNITY; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IMMUNOANGIOSTASIS; KIDNEY CARCINOMA; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR NECROSIS;

EID: 31144468057     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.3.1456     Document Type: Article

References (44)

1. American Cancer Society. 2004. Cancer Facts and Figures 2004: Selected Cancers. American Cancer Society, Atlanta, GA.
2. Pantuck, A. J., A. Zisman, F. Dorey, D. H. Chao, K. R. Han, J. Said, B. Gitlitz, A. S. Belldegrun, and R. A. Figlin. 2003. Renal cell carcinoma with retroperitoneal lymph nodes: impact on survival and benefits of immunotherapy. Cancer 97: 2995-3002.
3. Figlin, R. A. 1999. Renal cell carcinoma: management of advanced disease. J. Urol. 161: 381-386; discussion 386-387.
4. Negrier, S., B. Escudier, C. Lasset, J. Y. Douillard, J. Savary, C. Chevreau, A. Ravaud, A. Mercatello, J. Peny, M. Mousseau, et al. 1998. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338: 1272-1278.
5. Ravaud, A., N. Trufflandier, J. M. Ferriere, M. Debled, J. Palussiere, L. Cany, R. Gaston, S. Mathoulin-Pelissier, and B. N. Bui. 2003. Subcutaneous interleukin-2, interferon α-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. Br. J. Cancer 89: 2213-2218.
6. Verra, N., R. Jansen, G. Groenewegen, H. Mallo, M. J. Kersten, A. Bex, F. A. Vyth-Dreese, J. Sein, W. van de Kasteele, W. J. Nooijen, et al. 2003. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma. Br. J. Cancer 88: 1346-1351.
7. Belperio, J. A., M. P. Keane, D. A. Arenberg, C. L. Addison, J. E. Ehlert, M. D. Burdick, and R. M. Strieter. 2000. CXC chemokines in angiogenesis. J. Leukocyte Biol. 68: 1-8.
8. Strieter, R. M., J. A. Belperio, D. A. Arenberg, M. I. Smith, M. D. Burdick, and M. P. Keane. 2002. CXC chemokine in angiogenesis. Elsevier Science, Amsterdam.
9. Strieter, R. M., P. J. Polverini, S. L. Kunkel, D. A. Arenberg, M. D. Burdick, J. Kasper, J. Dzuiba, J. Van Damme, A. Walz, D. Marriott, et al. 1995. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270: 27348-27357.
10. Beider, K., A. Nagler, O. Wald, S. Franitza, M. Dagan-Berger, H. Wald, H. Giladi, S. Brocke, J. Hanna, O. Mandelboim, et al. 2003. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SC1D mice. Blood 102: 1951-1958.
11. Loetscher, M., B. Gerber, P. Loetscher, S. A. Jones, L. Piali, I. Clark-Lewis, M. Baggiolini, and B. Moser. 1996. Chemokine receptor specific for 1P10 and Mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184: 963-969.
12. Loetscher, M., P. Loetscher, N. Brass, E. Meese, and B. Moser. 1998. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur. J. Immunol. 28: 3696-3705.
13. Luster, A. D. 1998. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338: 436-445.
14. Moser, B., and P. Loetscher. 2001. Lymphocyte traffic control by chemokines. Nat. Immunol. 2: 123-128.
15. Qin, S., J. B. Rottman, P. Myers, N. Kassam, M. Weinblatt, M. Loetscher, A. E. Koch, B. Moser, and C. R. Mackay. 1998. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101: 746-754.
16. Rabin, R. L., M. K. Park, F. Liao, R. Swofford, D. Stephany, and J. M. Farber. 1999. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J. Immunol. 162: 3840-3850.
17. + T lymphocytes but not inhibition of angiogenesis. J. Immunother. 28: 343-351.
18. Huang, H., and J. Xiang. 2004. Synergistic effect of lymphotactin and interferon γ-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors. Int. J. Cancer. 109: 817-825.
19. + T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. 64: 7697-7701.
20. Sharma, S., M. Stolina, J. Luo, R. M. Strieter, M. Burdick, L. X. Zhu, R. K. Batra, and S. M. Dubinett. 2000. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164: 4558-4563.
21. Sharma, S., S. C. Yang, S. Hillinger, L. X. Zhu, M. Huang, R. K. Batra, J. F. Lin, M. D. Burdick, R. M. Strieter, and S. M. Dubinett. 2003. SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10. Mol. Cancer 2: 22.
22. Tannenbaum, C. S., R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, and T. A. Hamilton. 1998. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161: 927-932.
23. Wenzel, J., M. Uerlich, O. Haller, T. Bieber, and T. Tueting. 2005. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J. Cutan. Pathol. 32: 257-262.
24. Addison, C. L., D. A. Arenberg, S. B. Morris, Y. Y. Xue, M. D. Burdick, M. S. Mulligan, M. D. Iannettoni, and R. M. Strieter. 2000. The CXC chemokine, monokine induced by interferon-γ, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum. Gene Ther. 11: 247-261.
25. Arenberg, D. A., M. P. Keane, B. DiGiovine, S. L. Kunkel, S. B. Morris, Y. Y. Xue, M. D. Burdick, M. C. Glass, M. D. Iannettoni, and R. M. Strieter. 1998. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest 102: 465-472.
26. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, S. B. Morris, M. D. Burdick, M. C. Glass, D. T. Taub, M. D. Iannettoni, R. I. Whyte, and R. M. Strieter. 1996. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184: 981-992.
27. Burdick, M. D., L. A. Murray, M. P. Keane, Y. Y. Xue, D. A. Zisman, J. A. Belperio, and R. M. Strieter. 2005. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am. J. Respir. Crit. Care Med. 171: 261-268.
28. Yang, J., and A. Richmond. 2004. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 9: 846-855.
29. Belperio, J. A., M. P. Keane, M. D. Burdick, J. P. Lynch III, Y. Y. Xue, K. Li, D. J. Ross, and R. M. Strieter. 2002. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J. Immunol. 169: 1037-1049.
30. Belperio, J. A., M. P. Keane, M. D. Burdick, J. P. Lynch III, D. A. Zisman, Y. Y. Xue, K. Li, A. Ardehali, D. J. Ross, and R. M. Strieter. 2003. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J. Immunol. 171: 4844-4852.
31. Murphy, G. P., and W. J. Hrushesky. 1973. A murine renal cell carcinoma. J. Natl. Cancer Inst. 50: 1013-1025.
32. Hancock, W. W., B. Lu, W. Gao, V. Csizmadia, K. Faia, J. A. King, S. T. Smiley, M. Ling, N. P. Gerard, and C. Gerard. 2000. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192: 1515-1520.
33. Keane, M. P., J. A. Belperio, D. A. Arenberg, M. D. Burdick, Z. J. Xu, Y. Y. Xue, and R. M. Strieter. 1999. IFN-γ-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J. Immunol. 163: 5686-5692.
34. Belperio, J. A., M. P. Keane, M. D. Burdick, V. Londhe, Y. Y. Xue, K. Li, R. J. Phillips, and R. M. Strieter. 2002. Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J. Clin. Invest. 110: 1703-1716.
35. Keane, M. P., J. A. Belperio, Y. Y. Xue, M. D. Burdick, and R. M. Strieter. 2004. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol. 172: 2853-2860.
36. Hara, I., H. Nagai, H. Miyake, K. Yamanaka, S. Hara, M. J. Micallef, M. Kurimoto, K. Gohji, S. Arakawa, M. Ichihashi, and S. Kamidono. 2000. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther. 7: 83-90.
37. Dybal, E. J., G. P. Haas, R. L. Maughan, S. Sud, J. E. Pontes, and G. G. Hillman. 1992. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. J. Urol 148: 1331-1337.
38. Futami, H., L. Eader, T. T. Back, E. Gruys, H. A. Young, R. H. Wiltrout, and B. C. Baguley. 1992. Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives. J. Immunother. 12: 247-255.
39. Sonouchi, K., T. A. Hamilton, C. S. Tannenbaum, R. R. Tubbs, R. Bukowski, and J. H. Finke. 1994. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-α and interleukin-2. Am. J. Pathol. 144: 747-755.
40. Strieter, R. M., M. D. Burdick, B. N. Gomperts, J. A. Belperio, and M. P. Keane. 2005. CXC chemokines in angiogenesis. Cytokine. Growth Factor Rev. 16: 593-609.
41. Lasagni, L., M. Francalanci, F. Annunziato, E. Lazzeri, S. Giannini, L. Cosmi, C. Sagrinati, B. Mazzinghi, C. Orlando, E. Maggi, et al. 2003. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197: 1537-1549.
42. H1 priming. Nat. Immunol. 5: 1260-1265.
43. Taub, D. D., A. R. Lloyd, K. Conlon, J. M. Wang, J. R. Ortaldo, A. Harada, K. Matsushima, D. J. Kelvin, and J. J. Oppenheim. 1993. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med. 177: 1809-1814.
44. Whiting, D., G. Hsieh, J. J. Yun, A. Banerji, W. Yao, M. C. Fishbein, J. Belperio, R. M. Strieter, B. Bonavida, and A. Ardehali. 2004. Chemokine monokine induced by IFN-γ/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J. Immunol. 172: 7417-7424.